© 2001 by Oxford University Press
Journal of the National Cancer Institute, Vol. 93, No. 21, 1615-1623,
November 7, 2001
© 2001 Oxford University Press
ARTICLE |
Tamoxifen and Depression: More Evidence From the National Surgical Adjuvant Breast and Bowel Project's Breast Cancer Prevention (P-1) Randomized Study
Affiliations of authors: R. Day, J. P. Costantino, National Surgical Adjuvant Breast and Bowel Project Biostatistical Center, Pittsburgh, PA; P. A. Ganz, Jonsson Comprehensive Cancer Center, Los Angeles, CA.
Correspondence to: Richard Day, Ph.D., Department of Biostatistics, Graduate School of Public Health, 130 DeSoto St., University of Pittsburgh, Pittsburgh, PA 15261 (e-mail: day{at}nsabp.pitt.edu).
Background: Concerns have been raised that tamoxifen may be associated with depression. To investigate this question, we examined the psychological effects of tamoxifen treatment for breast cancer prevention on women at different levels of risk for clinical depression who were enrolled in the National Surgical Adjuvant Breast and Bowel Project's Breast Cancer Prevention (P-1) Study. Methods: A total of 11 064 women were randomly assigned to receive for 5 years daily doses of 20 mg of tamoxifen or placebo in the P-1 study, a multicenter, double-blind, placebo-controlled chemoprevention trial. Each woman was prospectively assessed for depression risk on the basis of medical history items collected at the baseline examination and placed in a high-, medium-, or low-risk group. Every 6 months, for a total of 36 months, the participants were assessed for depressive symptoms by completing the Center for Epidemiological Studies—Depression (CES-D) questionnaire. Scores of 16 or higher were indicative of an episode of affective distress. Differences between the risk groups and treatment arms were analyzed by logistic regression. All statistical tests were two-sided. Results: Women in the higher risk depression groups were more likely to score 16 or higher on the CES-D (percent follow-up examinations with a score of 
16: high-risk group = 35.7%, with 95% confidence interval [CI] = 32.5% to 38.9%; medium-risk group = 19.2%, with 95% CI = 18.1% to 20.3%; and low-risk group = 8.7%, with 95% CI = 8.3 to 9.1%) and to have these scores more frequently and for longer periods than women in the lower risk groups. Within each depression risk group, there was no difference in the proportion of women scoring 16 or higher by treatment assignment (tamoxifen versus placebo) (odds ratio = 0.98; 95% CI = 0.93 to 1.02). A post-hoc analysis indicated that the lack of a tamoxifen effect was not a result of differential missing data. Conclusions: Physicians need not be overly concerned that treatment with tamoxifen will increase the risk for or exacerbate existing depression in women. Nevertheless, physicians should continue to screen for and treat or refer potential cases of depression encountered in routine clinical practice.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  N. L. Henry, V. Stearns, D. A. Flockhart, D. F. Hayes, and M. Riba Drug Interactions and Pharmacogenomics in the Treatment of Breast Cancer and Depression Am J Psychiatry, October 1, 2008; 165(10): 1251 - 1255. [Full Text] [PDF]
|
|
|
|
 |
|
 K. C. Lee, G. T. Ray, E. M. Hunkeler, and P. R. Finley Tamoxifen Treatment and New-Onset Depression in Breast Cancer Patients Psychosomatics, June 1, 2007; 48(3): 205 - 210. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. R. Land, D. L. Wickerham, J. P. Costantino, M. W. Ritter, V. G. Vogel, M. Lee, E. R. Pajon, J. L. Wade III, S. Dakhil, J. B. Lockhart Jr, et al. Patient-Reported Symptoms and Quality of Life During Treatment With Tamoxifen or Raloxifene for Breast Cancer Prevention: The NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 Trial JAMA, June 21, 2006; 295(23): 2742 - 2751. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. A. Bardwell, L. Natarajan, J. E. Dimsdale, C. L. Rock, J. E. Mortimer, K. Hollenbach, and J. P. Pierce Objective Cancer-Related Variables Are Not Associated With Depressive Symptoms in Women Treated for Early-Stage Breast Cancer J. Clin. Oncol., June 1, 2006; 24(16): 2420 - 2427. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. J. Fabian and B. F. Kimler Selective Estrogen-Receptor Modulators for Primary Prevention of Breast Cancer J. Clin. Oncol., March 10, 2005; 23(8): 1644 - 1655. [Full Text] [PDF]
|
|
|
|
 |
|
 H. L. Rincavage, D. P. McDonnell, and C. M. Kuhn Expression of Functional Estrogen Receptor {beta} in Locus Coeruleus-Derived Cath.a Cells Endocrinology, July 1, 2003; 144(7): 2829 - 2835. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 V. G. Vogel, J. P. Costantino, D. L. Wickerham, and W. M. Cronin National Surgical Adjuvant Breast and Bowel Project Update: Prevention Trials and Endocrine Therapy of Ductal Carcinoma in Situ Clin. Cancer Res., January 1, 2003; 9(1): 495S - 501S. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. T. Chlebowski, N. Col, E. P. Winer, D. E. Collyar, S. R. Cummings, V. G. Vogel III, H. J. Burstein, A. Eisen, I. Lipkus, and D. G. Pfister American Society of Clinical Oncology Technology Assessment of Pharmacologic Interventions for Breast Cancer Risk Reduction Including Tamoxifen, Raloxifene, and Aromatase Inhibition J. Clin. Oncol., August 1, 2002; 20(15): 3328 - 3343. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 No Association Found Between Tamoxifen and Depression Journal Watch Psychiatry, February 21, 2002; 2002(221): 5 - 5. [Full Text]
|
|